Literature DB >> 32631992

Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies.

Claudia P Arevalo1, Valerie Le Sage2, Marcus J Bolton1, Theresa Eilola1, Jennifer E Jones2, Karen A Kormuth2, Eric Nturibi2, Angel Balmaseda3, Aubree Gordon4, Seema S Lakdawala2,5, Scott E Hensley6.   

Abstract

Immunity to influenza viruses can be long-lived, but reinfections with antigenically distinct viral strains and subtypes are common. Reinfections can boost antibody responses against viral strains first encountered in childhood through a process termed "original antigenic sin." It is unknown how initial childhood exposures affect the induction of antibodies against the hemagglutinin (HA) stalk domain of influenza viruses. This is an important consideration since broadly reactive HA stalk antibodies can protect against infection, and universal vaccine platforms are being developed to induce these antibodies. Here we show that experimentally infected ferrets and naturally infected humans establish strong "immunological imprints" against HA stalk antigens first encountered during primary influenza virus infections. We found that HA stalk antibodies are surprisingly boosted upon subsequent infections with antigenically distinct influenza A virus subtypes. Paradoxically, these heterosubtypic-boosted HA stalk antibodies do not bind efficiently to the boosting influenza virus strain. Our results demonstrate that an individual's HA stalk antibody response is dependent on the specific subtype of influenza virus that they first encounter early in life. We propose that humans are susceptible to heterosubtypic influenza virus infections later in life since these viruses boost HA stalk antibodies that do not bind efficiently to the boosting antigen.

Entities:  

Keywords:  hemagglutinin; influenza virus; original antigenic sin

Mesh:

Substances:

Year:  2020        PMID: 32631992      PMCID: PMC7382271          DOI: 10.1073/pnas.1920321117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Authors:  Sarah F Andrews; M Gordon Joyce; Michael J Chambers; Rebecca A Gillespie; Masaru Kanekiyo; Kwanyee Leung; Eun Sung Yang; Yaroslav Tsybovsky; Adam K Wheatley; Michelle C Crank; Jeffrey C Boyington; Madhu S Prabhakaran; Sandeep R Narpala; Xuejun Chen; Robert T Bailer; Grace Chen; Emily Coates; Peter D Kwong; Richard A Koup; John R Mascola; Barney S Graham; Julie E Ledgerwood; Adrian B McDermott
Journal:  Sci Immunol       Date:  2017-07-14

Review 2.  Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.

Authors:  Maryna C Eichelberger; David M Morens; Jeffery K Taubenberger
Journal:  Curr Opin Immunol       Date:  2018-04-16       Impact factor: 7.486

3.  Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem.

Authors:  Shanshan Lang; Jia Xie; Xueyong Zhu; Nicholas C Wu; Richard A Lerner; Ian A Wilson
Journal:  Cell Rep       Date:  2017-09-19       Impact factor: 9.423

4.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

5.  Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Authors:  M Gordon Joyce; Adam K Wheatley; Paul V Thomas; Gwo-Yu Chuang; Cinque Soto; Robert T Bailer; Aliaksandr Druz; Ivelin S Georgiev; Rebecca A Gillespie; Masaru Kanekiyo; Wing-Pui Kong; Kwanyee Leung; Sandeep N Narpala; Madhu S Prabhakaran; Eun Sung Yang; Baoshan Zhang; Yi Zhang; Mangaiarkarasi Asokan; Jeffrey C Boyington; Tatsiana Bylund; Sam Darko; Christopher R Lees; Amy Ransier; Chen-Hsiang Shen; Lingshu Wang; James R Whittle; Xueling Wu; Hadi M Yassine; Celia Santos; Yumiko Matsuoka; Yaroslav Tsybovsky; Ulrich Baxa; James C Mullikin; Kanta Subbarao; Daniel C Douek; Barney S Graham; Richard A Koup; Julie E Ledgerwood; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola; Adrian B McDermott
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

6.  Age-Related Pathology Associated with H1N1 A/California/07/2009 Influenza Virus Infection.

Authors:  Stephanie J Bissel; Chalise E Carter; Guoji Wang; Scott K Johnson; Lauren P Lashua; Alyson A Kelvin; Clayton A Wiley; Elodie Ghedin; Ted M Ross
Journal:  Am J Pathol       Date:  2019-10-01       Impact factor: 4.307

7.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

8.  Antibodies with 'Original Antigenic Sin' Properties Are Valuable Components of Secondary Immune Responses to Influenza Viruses.

Authors:  Susanne L Linderman; Scott E Hensley
Journal:  PLoS Pathog       Date:  2016-08-18       Impact factor: 6.823

9.  Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.

Authors:  Raffael Nachbagauer; Angela Choi; Ariana Hirsh; Irina Margine; Sayaka Iida; Aldo Barrera; Marcela Ferres; Randy A Albrecht; Adolfo García-Sastre; Nicole M Bouvier; Kimihito Ito; Rafael A Medina; Peter Palese; Florian Krammer
Journal:  Nat Immunol       Date:  2017-02-13       Impact factor: 25.606

10.  A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve.

Authors:  Ying Fu; Zhen Zhang; Jared Sheehan; Yuval Avnir; Callie Ridenour; Thomas Sachnik; Jiusong Sun; M Jaber Hossain; Li-Mei Chen; Quan Zhu; Ruben O Donis; Wayne A Marasco
Journal:  Nat Commun       Date:  2016-09-13       Impact factor: 14.919

View more
  18 in total

1.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

2.  Excess Winter Mortality (EWM) as a Dynamic Forensic Tool: Where, When, Which Conditions, Gender, Ethnicity and Age.

Authors:  Rodney P Jones
Journal:  Int J Environ Res Public Health       Date:  2021-02-23       Impact factor: 3.390

Review 3.  Immunology of SARS-CoV-2 infection in children.

Authors:  Janet Chou; Paul G Thomas; Adrienne G Randolph
Journal:  Nat Immunol       Date:  2022-02-01       Impact factor: 31.250

4.  Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Katharine H D Crawford; Adam S Dingens; Rachel Eguia; Caitlin R Wolf; Naomi Wilcox; Jennifer K Logue; Kiel Shuey; Amanda M Casto; Brooke Fiala; Samuel Wrenn; Deleah Pettie; Neil P King; Alexander L Greninger; Helen Y Chu; Jesse D Bloom
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

5.  Pre-existing heterosubtypic immunity provides a barrier to airborne transmission of influenza viruses.

Authors:  Valerie Le Sage; Jennifer E Jones; Karen A Kormuth; William J Fitzsimmons; Eric Nturibi; Gabriella H Padovani; Claudia P Arevalo; Andrea J French; Annika J Avery; Richard Manivanh; Elizabeth E McGrady; Amar R Bhagwat; Adam S Lauring; Scott E Hensley; Seema S Lakdawala
Journal:  PLoS Pathog       Date:  2021-02-18       Impact factor: 6.823

6.  H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.

Authors:  Juan Manuel Carreño; Shirin Strohmeier; Ericka Kirkpatrick Roubidoux; Rong Hai; Peter Palese; Florian Krammer
Journal:  mBio       Date:  2020-12-15       Impact factor: 7.867

Review 7.  The Intersection of Age and Influenza Severity: Utility of Ferrets for Dissecting the Age-Dependent Immune Responses and Relevance to Age-Specific Vaccine Development.

Authors:  Melissa Rioux; Magen E Francis; Cynthia L Swan; Anni Ge; Andrea Kroeker; Alyson A Kelvin
Journal:  Viruses       Date:  2021-04-15       Impact factor: 5.048

Review 8.  Protein engineering strategies for rational immunogen design.

Authors:  Timothy M Caradonna; Aaron G Schmidt
Journal:  NPJ Vaccines       Date:  2021-12-17       Impact factor: 7.344

Review 9.  Influenza immune escape under heterogeneous host immune histories.

Authors:  Rachel J Oidtman; Philip Arevalo; Qifang Bi; Lauren McGough; Christopher Joel Russo; Diana Vera Cruz; Marcos Costa Vieira; Katelyn M Gostic
Journal:  Trends Microbiol       Date:  2021-07-01       Impact factor: 17.079

10.  Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases.

Authors:  Marcos C Vieira; Celeste M Donato; Philip Arevalo; Guus F Rimmelzwaan; Timothy Wood; Liza Lopez; Q Sue Huang; Vijaykrishna Dhanasekaran; Katia Koelle; Sarah Cobey
Journal:  Nat Commun       Date:  2021-07-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.